Results 11 to 20 of about 55,081 (227)

NEW TENDENCIES IN MARKETING [PDF]

open access: yes, 2011
BACKGROUND: Vasospasm is the major cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage. It is well known that the vasoreactivity decreases with advancing age, but it is not well investigated in a large patient cohort whether, as a ...
Hans, Franz-Josef   +3 more
core   +1 more source

The roles of endoglin gene in cerebrovascular diseases. [PDF]

open access: yes, 2017
Endoglin (ENG, also known as CD105) is a transforming growth factor β (TGFβ) associated receptor and is required for both vasculogenesis and angiogenesis.
Ma, Li, Su, Hua, Zhang, Rui, Zhu, Wan
core   +2 more sources

Haemodynamic characterisation of different endotypes in coronary artery vasospasm in reaction to acetylcholine

open access: yesInternational Journal of Cardiology: Heart & Vasculature, 2022
Background: Vasoreactivity testing with high-dose acetylcholine is considered vasospasm provocation and low-dose as endothelial function testing. Aims: To assess the changes in reaction to low- and high-dose acetylcholine in the endotypes of CAS as ...
Rutger G.T. Feenstra   +12 more
doaj   +1 more source

Protein Transduction Method for Cerebrovascular Disorders [PDF]

open access: yes, 2009
Many studies have shown that a motif of 11 consecutive arginines (11R) is one of the most effective protein transduction domains (PTD) for introducing proteins into the cell membrane.
Arimitsu, Seiji   +9 more
core   +1 more source

Pulmonary vasospasm in systemic sclerosis: noninvasive techniques for detection [PDF]

open access: yes, 2014
In a subgroup of patients with systemic sclerosis (SSc), vasospasm affecting the pulmonary circulation may contribute to worsening respiratory symptoms, including dyspnea.
Giannarou, S   +8 more
core   +1 more source

Chronic Kidney Disease Stage Is a Modulator on the Association between High-Sensitivity C-Reactive Protein and Coronary Vasospastic Angina

open access: yesThe Scientific World Journal, 2014
The prevalence of coronary vasospasm and also the factors associated with coronary vasospasm in CKD is still unclear. In this cross-sectional study of 859 consecutive CKD patients with angina pectoris received coronary catheterization, we evaluated the ...
Heng-Jung Hsu   +11 more
doaj   +1 more source

Randomized, open-label, phase 1/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]) [PDF]

open access: yes, 2016
BACKGROUND AND PURPOSE—: We conducted a randomized, open-label, phase 1/2a, dose-escalation study of intraventricular sustained-release nimodipine (EG-1962) to determine safety, tolerability, pharmacokinetics, and clinical effects in aneurysmal ...
Aldrich, Francois   +10 more
core   +3 more sources

Difference in Transcranial Doppler Velocity and Patient Age between Proximal and Distal Middle Cerebral Artery Vasospasms after Aneurysmal Subarachnoid Hemorrhage

open access: yesCerebrovascular Diseases Extra, 2016
Background: Transcranial Doppler (TCD) is used to monitor cerebral vasospasm after subarachnoid hemorrhage (SAH), but its diagnostic ability is reported to be limited.
Misaki Kohama   +9 more
doaj   +1 more source

Management of cerebral vasospasm following aneurysmal subarachnoid hemorrhage

open access: yesSouthwest Respiratory and Critical Care Chronicles, 2017
Cerebral vasospasm is a serious complication following aneurysmal subarachnoid hemorrhage (SAH); it causes delayed cerebral ischemia (DCI) or infarction.
Mohamed Shehabeldin, Yazan Alderazi
doaj   +1 more source

Minimal long-term neurobehavioral impairments after endovascular perforation subarachnoid hemorrhage in mice [PDF]

open access: yes, 2017
Cognitive deficits are among the most severe and pervasive consequences of aneurysmal subarachnoid hemorrhage (SAH). A critical step in developing therapies targeting such outcomes is the characterization of experimentally-tractable pre-clinical models ...
Brody, David L   +5 more
core   +2 more sources

Home - About - Disclaimer - Privacy